Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma
Open Access
- 14 February 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 26 (6) , 823-831
Abstract
Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted within Milan criteria have outstanding outcomes with a 5‐ and 10‐year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor. There are also several studies showing how a subgroup of patients with tumors outside the Milan criteria might achieve comparable outcomes to patients within Milan criteria. In other words, the size and number of tumor nodules does not always reflect tumor biology, which could be better captured using molecular proxies for cancer aggressiveness. Over the last decade, we have significantly improved our understanding of the molecular landscape of early stage HCC. This includes the development of molecular classification, identification of prognostic and mutational signatures, and potential mechanisms of hepatocarcinogenesis. Some molecular markers have already proven useful to predict tumor‐related outcomes in HCC patients after LT. Most of these analyses are limited to tissue‐derived biomarkers, which limits their implementation in clinical practice because tissue biopsy is not required for HCC diagnosis. Minimally invasive alternative tools, such as liquid biopsy, are being increasingly explored and could help to individualize risk stratification for patients with HCC who will benefit from LT despite being outside the accepted clinical criteria.Keywords
Funding Information
- U.S. Department of War (CA150272P3)
This publication has 59 references indexed in Scilit:
- Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinomaInternational Journal of Cancer, 2013
- Micro RNA Expression Profiles as Adjunctive Data to Assess the Risk of Hepatocellular Carcinoma Recurrence After Liver TransplantationAmerican Journal of Transplantation, 2012
- Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular CarcinomaGastroenterology, 2011
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markersJournal of Hepatology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Fractional Allelic Imbalance Could Allow for the Development of An Equitable Transplant Selection Policy for Patients With Hepatocellular CarcinomaLiver Transplantation, 2008
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisNew England Journal of Medicine, 1996
- The Role of Liver Transplantation in Hepatobiliary Malignancy. A Retrospective Analysis of 95 Patients with Particular Regard to Tumor Stage and RecurrenceAnnals of Surgery, 1989
- Role of Liver Transplantation in Cancer TherapyAnnals of Surgery, 1985